Economic sustainability of nivolumab at flat dose for second-line treatment of metastatic non-small cell lung cancer in real life

Abstract

Get full access to this article

View all access options for this article.

References

Brahmer

Reckamp

Baas

, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123–135.

Borghaei

Paz-Ares

Horn

, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639.

Zhao

Suryawanshi

Hruska

, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 2017; 28: 2002–2008.

Opdivo Prescribing Information. Opdivo U.S. Product Information. Princeton, NJ: Bristol-Myers Squibb Company.

de Lemos ML, Kung C and Waignein S. Efficacy of nivolumab four-weekly dosing schedule based on body weight. J Oncol Pharm Pract 2019; 25: 961–963. https://www.ncbi.nlm.nih.gov/pubmed/?term=de+Lemos+ml+and+nivolumab.

Bayle

Besse

Annereau

, et al.

Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?

Eur J Cancer 2019; 113: 28–31.